Drug shortages present a serious dilemma for healthcare organizations. To s
uccessfully manage drug shortage situations, organizations need to have a s
tandardized, rational process in place. This article discusses the clinical
, ethical, and legal processes behind the development of a strategy to mana
ge limited supplies of a intravenous immunoglobulin (IVIG), Although the ex
ample is specific, the approach presented can be applied by other healthcar
e organizations to address other impending drug shortage situations.